Report Scope This report discusses the implications of all the above-mentioned trends in the context of the current size and growth of the market for generic drugs, both in global terms and broken down by the most important national markets.The nature and structure of the generic drug industry is discussed, with profiles of the leading 20+ generic drug companies and an update on M&A activity.
Five-year sales forecasts are provided for the national markets and the major therapeutic categories of the products involved.
Based on geography, the market has been segmented into North America, Europe, Asia-Pacific and Rest of the World. Detailed analyses of major countries such as the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China and India are covered in regional segments. For market estimates, data has been provided for the year 2019 as the base year, with forecasts for 2020 through 2025. The estimated values used are based on drug manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation.
Report Includes - 38 tables - An updated review of the global market for generic drugs - Analyses of the global market trends, with data from 2018-2020, and projections of compound annual growth rates (CAGRs) through 2025 - Highlights of current and future market potential of generic drugs along with an emphasis on the major generics issue, regulatory landscape and patent cliff within the generic drugs industry - COVID-19 impact (both short term vs. long term) on the global generic drugs market compared to the overall pharmaceutical industry - Estimation of the market size and market forecast for pharmaceuticals and generic drugs by the most important geographies and major therapeutic categories of products - Key M&A deals, collaborations and partnerships, licensing and manufacturing agreements, and other investment strategies within this market - Competitive landscape of the key players in the global generic drugs market, analysis of company sales data, and structure of the generics industry - Insight into the pipeline analysis of new and generic drugs and their impact on the growth of the market - Company profiles of the leading players operating in global generic drugs market including Aspen, Cipla, Lupin, Pfizer, Sanofi, Sun Pharmaceuticals and Teva Pharmaceuticals
Summary This report is being published at a time when the pharmaceutical industry faces challenges and changes more radical than any it has faced in the last half-century.The worldwide economic recession in 2008 has had a profound impact on an industry that is normally resilient to the usual ups and downs of commercial life.
Apart from the sometimes-painful process of cutting costs and restructuring, the industry has had to confront the fact that its trading environment has fundamentally changed because all its customers are now aware of prices.
At this critical time, the pharmaceutical world has also endured a phase for which the label “patent cliff” was coined.A stream of blockbuster drugs has begun losing their patent protection, and R&D pipelines have not been able to produce a satisfactory supply of replacements.
The doors have been thrown open to generic drug producers to do what they do best: provide low-cost alternatives.
And there is an added complexity.Over the past two decades, advances in biotechnology have led to the introduction of a generation of biotherapeutic agents that are often more efficacious than traditional small-molecule drugs at treating their target diseases.
The earliest of these biotherapeutics are now losing their patent protection, and this offers yet another opportunity for generic copies—although this is a technically fraught area, as will be seen. In fact, the challenges facing “originator” companies—the major purveyors of own-brand pharmaceuticals—are matched by those confronting generic drug suppliers.
Suppliers of generic drugs relied initially on low cost as their main market advantage.It became a potent argument, as the government health departments in most European countries operating national health schemes began to introduce measures designed to curb pharmaceutical expenditure.
In the U.S., developments in managed care had a similar effect. Everywhere, these cost-cutting exercises favored generics.
However, the low-cost argument that had been the generic products’ main rationale acted against the commercial promise of this industry sector.This occurred partly because the attractiveness (and thus high-volume sales potential) of blockbuster drugs remained in place after these drugs lost their patent cover.
Generic drug companies vied with each other to introduce low-cost copies, and they were driven to undercut each other to the point where a year after patent expiry on the original brand, the mean price of copy products was merely 20% or less of the original.
Partly, too, generic price competition was fueled by government reimbursement measures, which favored low-cost drugs and thus tended to trigger further price cutting among the generic drug contenders.
This development had two far-reaching effects.First, it began to weed out the weaker generic drug companies in favor of companies that had the means and the resolve to exist in an environment where profit margins were severely cut, sometimes to less than 10%.
One of the survival strategies adopted by these manufacturers has been to widen their appeal beyond mere cost-cutting, to include, for example, “super generics” products with added value, often in the form of special delivery formulations.
Our reports have been used by over 10K customers, including:
Receptor Activity Modifying Protein 2 (Calcitonin Receptor Like Receptor Activity Modifying Protein 2 or CRLR Activity Modifying Protein 2 or RAMP2) - Drugs in Development, 2021 Summary Receptor Activity Modifying Protein 2 (Calcitonin Receptor Like Receptor Activity Modifying Protein 2 or CRLR Activity...
The global generic drugs market reached a value of US$ 386 Billion in 2020. A generic drug is a medicine that contains the same active ingredient and has an equivalent therapeutic effect as the branded drug. It is also identical in terms of safety, quality, dosage, strength, route of administration, intended use, effect,...
The Global Telmisartan Market size is expected to reach $4 billion by 2026, rising at a market growth of 5.8% CAGR during the forecast period. Telmisartan refers to an angiotensin receptor blocker (ARB) utilized alone or combined with other agents in order to treat stroke management, cardiac arrest, and hypertension. Telmisartan is available...
285 pages •
By Global Industry Analysts
• May 2021
- Global Generic Drugs Market to Reach US$536.4 Billion by the Year 2027
- Amid the COVID-19 crisis, the global market for Generic Drugs estimated at US$365.9 Billion in the year 2020, is projected to reach a revised size of US$536.4 Billion by 2027, growing at a CAGR of 5.6% over...
Receptor Activity Modifying Protein 1 (Calcitonin Receptor Like Receptor Activity Modifying Protein 1 or RAMP1) - Drugs in Development, 2021 Summary Receptor Activity Modifying Protein 1 (Calcitonin Receptor Like Receptor Activity Modifying Protein 1 or RAMP1) - Drugs in Development, 2021 provides...
Receptor Activity Modifying Protein 3 (Calcitonin Receptor Like Receptor Activity Modifying Protein 3 or RAMP3) - Drugs in Development, 2021 Summary Receptor Activity Modifying Protein 3 (Calcitonin Receptor Like Receptor Activity Modifying Protein 3 or RAMP3) - Drugs in Development, 2021 provides...
Coagulation Factor VII (Proconvertin or Serum Prothrombin Conversion Accelerator or SPCA or Eptacog Alfa or F7 or EC 220.127.116.11) - Drugs in Development, 2021 Summary Coagulation Factor VII (Proconvertin or Serum Prothrombin Conversion Accelerator or SPCA or Eptacog Alfa or F7 or EC 18.104.22.168) - Drugs...
120 pages •
By Infiniti Research Limited
• Apr 2021
Analytical instrument market in US 2021-2025 The analyst has been monitoring the analytical instrument market in the US and it is poised to grow by $ 5.57 bn during 2021-2025, progressing at a CAGR of almost 3% during the forecast period. Our report on analytical instrument market in the US provides a holistic analysis, market size and...
Generic injectables are bio-equivalents of their branded counterparts which are not protected by drug patents. They are as safe and effective as the innovator drugs since they have similar active ingredient, dosage, strength, quality, form, etc. Although the manufacturing of generic injectables is complex, their R&D...
Research And Development
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.